دورية أكاديمية
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
| العنوان: | Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. |
|---|---|
| المؤلفون: | Mwesigwa B; Makerere University Walter Reed Project, Kampala, Uganda., Houser KV; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: katherine.houser@nih.gov., Hofstetter AR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ortega-Villa AM; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Naluyima P; Makerere University Walter Reed Project, Kampala, Uganda., Kiweewa F; Makerere University Walter Reed Project, Kampala, Uganda., Nakabuye I; Makerere University Walter Reed Project, Kampala, Uganda., Yamshchikov GV; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Andrews C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., O'Callahan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Strom L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Schech S; Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Anne Eller L; Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Sondergaard EL; Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Scott PT; Walter Reed Army Institute of Research, Silver Spring, MD, USA., Amare MF; Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Modjarrad K; Walter Reed Army Institute of Research, Silver Spring, MD, USA., Wamala A; Makerere University Walter Reed Project, Kampala, Uganda., Tindikahwa A; Makerere University Walter Reed Project, Kampala, Uganda., Musingye E; Makerere University Walter Reed Project, Kampala, Uganda., Nanyondo J; Makerere University Walter Reed Project, Kampala, Uganda., Gaudinski MR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Gordon IJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Holman LA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Saunders JG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Costner PJM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mendoza FH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Happe M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Morgan P; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Plummer SH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hickman SP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Vazquez S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Murray T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Cordon J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Dulan CNM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hunegnaw R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Basappa M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Padilla M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Gajjala SR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Swanson PA 2nd; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Coates EE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Gall JG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ploquin A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Kibuuka H; Makerere University Walter Reed Project, Kampala, Uganda., Ake JA; Walter Reed Army Institute of Research, Silver Spring, MD, USA., Ledgerwood JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. |
| مؤلفون مشاركون: | RV 508 Study Team |
| المصدر: | The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Dec; Vol. 23 (12), pp. 1408-1417. Date of Electronic Publication: 2023 Aug 03. |
| نوع المنشور: | Clinical Trial, Phase I; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001- |
| مواضيع طبية MeSH: | Hemorrhagic Fever, Ebola*/prevention & control , Ebola Vaccines* , Ebolavirus*/genetics , Adenoviruses, Simian*/genetics, Animals ; Humans ; Adult ; Pan troglodytes ; Uganda ; Sudan ; Antibodies, Viral ; Adenoviridae/genetics ; Glycoproteins ; Immunogenicity, Vaccine ; Double-Blind Method |
| مستخلص: | Background: Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and therapeutics specific for Zaire Ebola virus have been approved for use during outbreak situations, Sudan Ebola virus is an antigenically distinct virus with no approved vaccines available. Methods: In this phase 1, open-label, dose-escalation trial we evaluated the safety, tolerability, and immunogenicity of a monovalent chimpanzee adenovirus 3 vaccine against Sudan Ebola virus (cAd3-EBO S) at Makerere University Walter Reed Project in Kampala, Uganda. Study participants were recruited from the Kampala metropolitan area using International Review Board-approved written and electronic media explaining the trial intervention. Healthy adults without previous receipt of Ebola, Marburg, or cAd3 vectored-vaccines were enrolled to receive cAd3-EBO S at either 1 × 10 10 or 1 × 10 11 particle units (PU) in a single intramuscular vaccination and were followed up for 48 weeks. Primary safety and tolerability endpoints were assessed in all vaccine recipients by reactogenicity for the first 7 days, adverse events for the first 28 days, and serious adverse events throughout the study. Secondary immunogenicity endpoints included evaluation of binding antibody and T-cell responses against the Sudan Ebola virus glycoprotein, and neutralising antibody responses against the cAd3 vector at 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT04041570, and is completed. Findings: 40 healthy adults were enrolled between July 22 and Oct 1, 2019, with 20 receiving 1 × 10 10 PU and 20 receiving 1 × 10 11 PU of cAd3-EBO S. 38 (95%) participants completed all follow-up visits. The cAd3-EBO S vaccine was well tolerated with no severe adverse events. The most common reactogenicity symptoms were pain or tenderness at the injection site (34 [85%] of 40), fatigue (29 [73%] of 40), and headache (26 [65%] of 40), and were mild to moderate in severity. Positive responses for glycoprotein-specific binding antibodies were induced by 2 weeks in 31 (78%) participants, increased to 34 (85%) participants by 4 weeks, and persisted to 48 weeks in 31 (82%) participants. Most participants developed glycoprotein-specific T-cell responses (20 [59%, 95% CI 41-75] of 34; six participants were removed from the T cell analysis after failing quality control parameters) by 4 weeks after vaccination, and neutralising titres against the cAd3 vector were also increased from baseline (90% inhibitory concentration of 47, 95% CI 30-73) to 4 weeks after vaccination (196, 125-308). Interpretation: The cAd3-EBO S vaccine was safe at both doses, rapidly inducing immune responses in most participants after a single injection. The rapid onset and durability of the vaccine-induced antibodies make this vaccine a strong candidate for emergency deployment in Sudan Ebola virus outbreaks. Funding: National Institutes of Health via interagency agreement with Walter Reed Army Institute of Research. Competing Interests: Declaration of interests NJS is listed on patents involving cAd3-vectored vaccines. All other authors declare no competing interests. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| التعليقات: | Erratum in: Lancet Infect Dis. 2023 Oct;23(10):e400. (PMID: 37652067) |
| References: | J Infect Dis. 2015 Feb 15;211(4):549-57. (PMID: 25225676) J Virol. 2004 Oct;78(19):10370-7. (PMID: 15367603) Nat Med. 2014 Oct;20(10):1126-9. (PMID: 25194571) Nat Rev Dis Primers. 2020 Feb 20;6(1):13. (PMID: 32080199) Viruses. 2016 May 11;8(5):. (PMID: 27187443) PLoS Pathog. 2021 Dec 9;17(12):e1010078. (PMID: 34882741) Sci Transl Med. 2012 Jan 4;4(115):115ra2. (PMID: 22218691) N Engl J Med. 2017 Mar 9;376(10):928-938. (PMID: 25426834) Lancet Infect Dis. 2016 Jan;16(1):31-42. (PMID: 26546548) J Infect Dis. 2007 Nov 15;196 Suppl 2:S329-36. (PMID: 17940968) J Immunol. 2013 Mar 15;190(6):2720-35. (PMID: 23390298) Future Microbiol. 2020 Jan;15:85-106. (PMID: 32030996) Lancet Infect Dis. 2022 Jan;22(1):8-10. (PMID: 34529960) Vaccines (Basel). 2019 Jan 22;7(1):. (PMID: 30678246) Lancet. 2023 Jan 28;401(10373):294-302. (PMID: 36709074) Vaccines (Basel). 2022 Jul 29;10(8):. (PMID: 36016099) PLoS One. 2022 Oct 5;17(10):e0274906. (PMID: 36197845) Sci Transl Med. 2022 Dec 14;14(675):eabq6364. (PMID: 36516269) Vaccines (Basel). 2022 Sep 01;10(9):. (PMID: 36146524) Nat Med. 2005 Jul;11(7):786-90. (PMID: 15937495) Vaccine. 2010 Dec 16;29(2):304-13. (PMID: 21034824) Lancet. 2015 Apr 18;385(9977):1545-54. (PMID: 25540891) |
| معلومات مُعتمدة: | Z99 AI999999 United States ImNIH Intramural NIH HHS |
| فهرسة مساهمة: | Investigator: J Namugabo; C Beingana; MG Mukyala; J Wandege; C Nanteza; B Atwijuka; J Kizanye; G Nassanga; J Namuli; H Kityo; M Ssekitoleko; R Nassaka; H Mutebe; M Kabahubya; AT Widge; SE O'Connell; O Amoa-Awua; SR Narpala; B Flach; J Cox; A Beck; M Guech; E Seo; JA Stein |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04041570 |
| المشرفين على المادة: | 0 (Ebola Vaccines) 0 (Antibodies, Viral) 0 (Glycoproteins) |
| تواريخ الأحداث: | Date Created: 20230806 Date Completed: 20231127 Latest Revision: 20240218 |
| رمز التحديث: | 20240218 |
| مُعرف محوري في PubMed: | PMC10837320 |
| DOI: | 10.1016/S1473-3099(23)00344-4 |
| PMID: | 37544326 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1474-4457 |
|---|---|
| DOI: | 10.1016/S1473-3099(23)00344-4 |